Abbvie Inc. vs Charles River Laboratories International, Inc.
ABBV vs CRL — side-by-side comparison from reported financials. ABBV leads 6, CRL leads 4 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Charles River Laboratories International, Inc.
CRL · Healthcare
$301.79+1.27%Strained
| Metric | ABBV | CRL |
|---|---|---|
| Price | $276.43 | $301.79 |
| Market cap | $488B | $14.4B |
| Revenue (TTM) | $64.4B | $4.00B |
| Revenue growth | +1.8% | +0.3% |
| Net margin | 9.8% | -6.0% |
| Free cash flow | $18.2B | $371M |
| Net cash (debt) | ($56.2B) | ($1.92B) |
| 1-year price return | +19.8% | +75.3% |
| P/E | 77.4 | 20.8 |
| P/E vs own history (cheap-side %) | 23% | 98% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | -8% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 5 of 11 |
| Employees | 57,000 | 19,700 |
Full résumé-style profiles: ABBV CV · CRL CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.